The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes—A Single-Center Longitudinal Cohort Analysis

<b>Objectives</b>-chronic graft vs. host disease (cGVHD) is associated with substantial morbidity and mortality. We aimed to analyze advances in treatment strategy and outcomes during the last decade due to the incorporation of novel immunosuppressive therapy (IST) drugs in the armamentarium. <b>Methods</b>-we retrospectively analyzed all patients > 18 years with cGVHD after their first hematopoietic cell transplantation (HCT) between 2012 and 2020 (n = 91), divided into three treatment periods: 2012-2014, 2015-2017, and 2018-2020 (groups 1, 2, and 3, respectively). <b>Results</b>-mean cumulative steroid dose and dose/total cGVHD-treatment days was lower in groups 2-3 compared to 1 (<i>p</i> = 0.008 and <i>p</i> = 0.042, respectively). The median IST-free survival was 79 (95%CI54-94) months, with more patients in group 3 (47% (95%CI 25-54%) discontinuing IST at 3 years, <i>p</i> = 0.1). Groups 2-3 compared to 1 had better glycemic control (<i>p</i> < 0.01), higher bone density (<i>p</i> = 0.06), and fewer cardiovascular events. The number of admissions/patient dropped from 0.7/year in group 1 to 0.24/year and 0.36/year in groups 2-3, respectively (<i>p</i> = 0.36). Employment reintegration was higher in groups 2-3 compared with 1 (<i>p</i> = 0.05) and so was earlier return to work (<i>p</i> = 0.01). There were no differences in survival outcomes. <b>Conclusions</b>-the incorporation of novel agents appears to be associated with reduced overall steroid burden, improved cGVHD control, and fewer long-term side effects.